The Goldman Sachs Group Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $15.00
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target reduced by equities researchers at The Goldman Sachs Group from $29.00 to $15.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective suggests a potential upside of 73.21% […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target reduced by equities researchers at The Goldman Sachs Group from $29.00 to $15.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective suggests a potential upside of 73.21% […]
